- Home
- QNRX vs PCSA Comparison
QNRX vs PCSA Comparison
Compare QNRX & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- PCSA
- Stock Information
- Founded
- QNRX 2018
- PCSA 2011
- Country
- QNRX United States
- PCSA United States
- Employees
- QNRX N/A
- PCSA N/A
- Industry
- QNRX Medical/Dental Instruments
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- PCSA Health Care
- Exchange
- QNRX Nasdaq
- PCSA Nasdaq
- Market Cap
- QNRX 3.3M
- PCSA 3.3M
- IPO Year
- QNRX N/A
- PCSA N/A
- Fundamental
- Price
- QNRX $9.60
- PCSA $0.22
- Analyst Decision
- QNRX
- PCSA Strong Buy
- Analyst Count
- QNRX 0
- PCSA 1
- Target Price
- QNRX N/A
- PCSA $6.00
- AVG Volume (30 Days)
- QNRX 12.9K
- PCSA 46.5M
- Earning Date
- QNRX 08-07-2025
- PCSA 08-12-2025
- Dividend Yield
- QNRX N/A
- PCSA N/A
- EPS Growth
- QNRX N/A
- PCSA N/A
- EPS
- QNRX N/A
- PCSA N/A
- Revenue
- QNRX N/A
- PCSA N/A
- Revenue This Year
- QNRX N/A
- PCSA N/A
- Revenue Next Year
- QNRX N/A
- PCSA N/A
- P/E Ratio
- QNRX N/A
- PCSA N/A
- Revenue Growth
- QNRX N/A
- PCSA N/A
- 52 Week Low
- QNRX $5.01
- PCSA $0.15
- 52 Week High
- QNRX $54.95
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- QNRX 64.78
- PCSA 44.28
- Support Level
- QNRX $8.04
- PCSA $0.20
- Resistance Level
- QNRX $8.58
- PCSA $0.33
- Average True Range (ATR)
- QNRX 0.46
- PCSA 0.09
- MACD
- QNRX 0.04
- PCSA -0.01
- Stochastic Oscillator
- QNRX 98.57
- PCSA 6.53
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).